Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "enkephalin" wg kryterium: Temat


Wyświetlanie 1-5 z 5
Tytuł:
Potencjalne zastosowanie enkefalin w diagnostyce i terapii różnych chorób
Potential application enkephalns in diagnostics and treatment of various diseases
Autorzy:
Sobocińska, M.
Kamysz, E.
Powiązania:
https://bibliotekanauki.pl/articles/172068.pdf
Data publikacji:
2017
Wydawca:
Polskie Towarzystwo Chemiczne
Tematy:
endogenne peptydy opioidowe
enkefaliny
Leu-enkefalina
Met-enkefalina
endogenous opioid peptides
enkephalins
Met-enkephalin
Leu-enkephalin
Opis:
For the past few years enkephalins have been a center of appreciation and interest. Enkephalins were discovered in 1975 by Hughes, Kosterlitz and coworkers [1]. They can be described as short sequences of amino acids that are naturally produced in the central nervous system (CNS) in various glands throughout the body, such as the pituitary and adrenal glands [7, 9]. There were revealed two forms of enkephalins, one containing leucine, and the other containing methionine. Enkephalins are produced by the cleavage of a precursor protein called proenkephalin. From proenkephalin originate Met- and Leu-enkephalin, Met-enkephalin-Arg6-Gly7- -Leu8, Met-enkephalin-Arg6-Phe7 [1–3]. Enkephalins are involved in phenomena associated with modulated pain perception [13], regulation of memory and emotional conditions [21] and regulation of immunological system [29]. They also have an impact on the cardiovascular system [17], motility of the digestive system and metabolism of carbohydrates [8]. This article is a review of the current knowledge about enkephalins and their usage in the diagnostics and treatment of a variety of diseases: diseases/disorders of the central nervous system [21, 22], Parkinson’s disease [27], disease of the immune system [29], chronic pain [12], tumor diseases/cancer [33], heart and cardiovascular diseases [19] and inflammatory bowel disease [23].
Źródło:
Wiadomości Chemiczne; 2017, 71, 1-2; 33-44
0043-5104
2300-0295
Pojawia się w:
Wiadomości Chemiczne
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Fluorescence decay time distribution analysis of cyclic enkephalin analogues; Influence of solvent and Leu configuration in position 5 on conformation
Autorzy:
Malicka, Joanna
Ganzynkowicz, Robert
Groth, Małgorzata
Czaplewski, Cezary
Karolczak, Jerzy
Liwo, Adam
Wiczk, Wiesław
Powiązania:
https://bibliotekanauki.pl/articles/1044169.pdf
Data publikacji:
2001
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
lifetime distribution
fluorescence
energy transfer
conformation
enkephalin
Opis:
Lifetime distribution analysis were performed to study the influence of Leu configuration in position 5 on changes of the peptide chain of cyclic analogues of enkephalins containing a fluorescence donor and acceptor in different solvents. The configuration change of Leu5 in all the analogues of enkephalins studied which contain donor-acceptor pairs has no apparent influence on Trp lifetime distributions. In contrast, there is a significant solvent effect on the shape of lifetime distribution.
Źródło:
Acta Biochimica Polonica; 2001, 48, 1; 95-102
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
A novel cis-peptide bond motif inducing β-turn type VI. The synthesis of enkephalin analogues modified with 4-aminopyroglutamic acid.
Autorzy:
Kaczmarek, Krzysztof
Kaleta, Maciej
Chung, Nga
Schiller, Peter
Zabrocki, Janusz
Powiązania:
https://bibliotekanauki.pl/articles/1044069.pdf
Data publikacji:
2001
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
constrained enkephalin analogues
4-aminopyroglutamic acid
cis-peptide bond
β-turn mimetic
Opis:
A new pathway leading to a mixture of four isomers of 4-aminopyroglutamic acid is described. Michael type addition of Z-ΔAla-OMe to enolates prepared from acylaminomalonates, followed by hydrolysis and decarboxylation give protected 4-aminopyroglutamic acid with the 4-aminopyroglutamic acid with the cis:trans ratio approximately 3:2. This mixture was incorporated into Leu-enkephalin (position 2-3). After separation of peptides it appeared that all analogues were essentially inactive in guinea pig ileum and mouse vas deferens bioassays.
Źródło:
Acta Biochimica Polonica; 2001, 48, 4; 1159-1163
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Influence of the central histaminergic systems on the pituitary-adrenocortical response to met-enkephalinamide
Autorzy:
Bugajski, J
Turon, M.
Gadek-Michalska, A.
Olowska, A.
Powiązania:
https://bibliotekanauki.pl/articles/70580.pdf
Data publikacji:
1995
Wydawca:
Polskie Towarzystwo Fizjologiczne
Tematy:
hypothalamic histamine
central histaminergic system
brain
endorphin
dopamine
noradrenaline
endogenous enkephalin
histamine receptor
met-enkephalinamide
pituitary-adrenocortical response
opioid receptor
corticosterone
alpha-Fluoromethylhistidine
Źródło:
Journal of Physiology and Pharmacology; 1995, 46, 3
0867-5910
Pojawia się w:
Journal of Physiology and Pharmacology
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Charakterystyka endogennych inhibitorów enzymów rozkładających enkefaliny
Characteristic of the endogenous enkephalin degrading enzymes inhibitors
Autorzy:
Sobocińska, M.
Maćkiewicz, Z.
Powiązania:
https://bibliotekanauki.pl/articles/171530.pdf
Data publikacji:
2014
Wydawca:
Polskie Towarzystwo Chemiczne
Tematy:
inhibitory
inhibitory enzymów rozkładających enkefaliny
Els
endogenne inhibitory enzymów rozkładających enkefaliny
opiody
peptydy
ból
środki przeciwbólowe
inhibitors
endogenous enkephalin degrading enzymes inhibitors
opioid
peptides
pain
analgesicagents
Opis:
Management of acute and chronic pain has always been a key area of clinical research. Pain and stress stimulation may cause an increase in the level of endogenous opioids in the body. Endogenous enkephalins activate opioid receptors in the brain, leading to the analgesic effect. Enkephalinases inactivate endogenous opioids, abolishing their activity. Enkephalin degrading enzyme inhibitors (EIs) in turn inhibit these enzymes, preventing them from degrading endogenous enkephalins what leads to analgesia. The enkephalin degrading enzyme inhibitors seem to be promising analgesic agents [2]. Analgesic effect of EIs has been discovered recently and their therapeutic potential has not been effectively investigated yet. The main advantage of enkephalinase inhibitors is that they do not show adverse effects characteristic for opioids. EIs play an important role in modulating nociception, so they are potential agents for the treatment of acute and chronic pain. They often possess also additional antidiarrheal, antidepressant and anticancer properties [3]. The potential EIs targets appear to be aminopeptidase N (APN), dipeptidyl peptidase III (DPP III), angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) [4]. EIs may be broadly classified as endogenous and those that are obtained synthetically [4]. The purpose of this work is to present a review of endogenous enkephalinase inhibitors: sialorphin, opiorphin, and spinorphin. Sialorphin (Gln-His-Asn-Pro-Arg) is synthesized predominantly in the submandibular gland and prostate of adult rats in response to androgen steroids and is released locally and systemically in response to stress. Sialorphin protects endogenous enkephalins released after nociceptive stimuli by inhibiting NEP in vivo. Sialorphin prevents spinal and renal NEP from breaking down substance P and Met-enkephalin in vitro. Sialorphin suppressed pain sensation for both chemical- -induced inflammation and acute physical pain [8, 9, 12]. Opiorphin (Gln-Arg-Phe-Ser-Arg) is an endogenous chemical compound first isolated from human saliva. Opiorphin is a natural analgesic. Opiorphin protects enkephalins from degradation by human neutral endopeptidase and aminopeptidase N. Opiorphin is closely related to the rat sialorphin peptide [12, 13, 19]. Spinorphin (Leu-Val-Val-Tyr-Pro-Trp-Thr) has been isolated from the bovine spinal cord as an endogenous inhibitor of enkephalin - degrading enzymes. Spinorphin is an antagonist of the P2X3 receptor and a weak partial agonist/antagonist of the FP1 receptor [24, 25, 26].
Źródło:
Wiadomości Chemiczne; 2014, 68, 3-4; 317-327
0043-5104
2300-0295
Pojawia się w:
Wiadomości Chemiczne
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-5 z 5

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies